EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 28 / Numéro 11 (Novembre 2012) Med Sci (Paris), 28 11 (2012) 963-969 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Numéro 11, Novembre 2012
Page(s) 963 - 969
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20122811015
Publié en ligne 12 novembre 2012
  1. Segal BH, Leto TL, Gallin JI, et al. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000 ; 79 : 170–200. [CrossRef] [PubMed] [Google Scholar]
  2. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000 ; 79 : 155–169. [CrossRef] [PubMed] [Google Scholar]
  3. Seger RA. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med 2010 ; 68 : 334–340. [PubMed] [Google Scholar]
  4. Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease (CGD). J Clin Immunol 2008 ; 28 : 67–72. [CrossRef] [Google Scholar]
  5. Matute JD, Arias AA, Wright NAM, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009 ; 114 : 3309–3315. [CrossRef] [PubMed] [Google Scholar]
  6. Ambruso DR, Knall C, Abell AN, et al. Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proc Natl Acad Sci USA 2000 ; 97 : 4654–4659. [CrossRef] [Google Scholar]
  7. Levine S, Smith VV, Malone M, et al. Histopathological features of chronic granulomatous disease (CGD) in childhood. Histopathology 2005 ; 47 : 508–516. [CrossRef] [PubMed] [Google Scholar]
  8. Dennis CG, Greco WR, Brun Y, et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicro Agents Chemother 2006 ; 50 : 422–427. [CrossRef] [Google Scholar]
  9. Segal BH, Veys P, Malech H, et al. Chronic granulomatous disease: lessons from a rare disorder. Biol Blood Marrow Transplant 2011 ; 17 : S123–S131. [CrossRef] [PubMed] [Google Scholar]
  10. D’Angelo C, Luca A De, Zelante T, et al. Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J Immunol 2009 ; 183 : 4609–4618. [CrossRef] [PubMed] [Google Scholar]
  11. Montagnoli C, Fallarino F, Gaziano R, et al. Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism. J Immunol 2006 ; 176 : 1712–1723. [PubMed] [Google Scholar]
  12. Heitger A. Regulation of expression and function of IDO in human dendritic cells. Curr Med Chem 2011 ; 18 : 2222–2233. [CrossRef] [PubMed] [Google Scholar]
  13. Bianchi M, Hakkim A, Brinkmann V, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood 2009 ; 114 : 2619–2622. [CrossRef] [PubMed] [Google Scholar]
  14. Beauté J, Obenga G, Mignot L Le, et al. Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: a multicenter study in France. Pediatr Infect Dis J 2011 ; 30 : 57–62. [CrossRef] [PubMed] [Google Scholar]
  15. Blumental S, Mouy R, Mahlaoui N, et al. Invasive mold infections in chronic granulomatous disease: a 25-year retrospective survey. Clin Infect Dis 2011 ; 53 : e159–e169. [CrossRef] [PubMed] [Google Scholar]
  16. Segal BH, DeCarlo ES, Kwon-Chung KJ, et al. Aspergillus nidulans infection in chronic granulomatous disease. Medicine (Baltimore) 1998 ; 77 : 345–354. [CrossRef] [PubMed] [Google Scholar]
  17. Verweij PE, Varga J, Houbraken J, et al. Emericella quadrilineata as cause of invasive aspergillosis. Emerging Infect Dis 2008 ; 14 : 566–572. [CrossRef] [PubMed] [Google Scholar]
  18. Verweij PE, Warris A, Weemaes CM. Preventing fungal infections in chronic granulomatous disease. N Engl J Med 2003 ; 349 : 1190–1191. [CrossRef] [Google Scholar]
  19. Wildenbeest JG, Oomen MW, Brüggemann RJ, et al. Rhizopus oryzae skin infection treated with posaconazole in a boy with chronic granulomatous disease. Pediatr Infect Dis J 2010 ; 29 : 578. [CrossRef] [Google Scholar]
  20. Ravin SS De, Challipalli M, Anderson V, et al. Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. Clin Infect Dis 2011 ; 52 : e136–e143. [CrossRef] [PubMed] [Google Scholar]
  21. Machouart M, Garcia-Hermoso D, Rivier A, et al. Emergence of disseminated infections due to Geosmithia argillacea in patients with chronic granulomatous disease receiving long-term azole antifungal prophylaxis. J Clin Microbiol 2011 ; 49 : 1681–1683. [CrossRef] [PubMed] [Google Scholar]
  22. Snelgrove RJ, Edwards L, Williams AE, et al. In the absence of reactive oxygen species, T cells default to a Th1 phenotype and mediate protection against pulmonary Cryptococcus neoformans infection. J Immunol 2006 ; 177 : 5509–5516. [PubMed] [Google Scholar]
  23. Verweij PE, Weemaes CM, Curfs JH, et al. Failure to detect circulating Aspergillus markers in a patient with chronic granulomatous disease and invasive aspergillosis. J Clin Microbiol 2000 ; 38 : 3900–3901. [PubMed] [Google Scholar]
  24. Siddiqui S, Anderson VL, Hilligoss DM, et al. Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease. Clin Infect Dis 2007 ; 45 : 673–681. [CrossRef] [PubMed] [Google Scholar]
  25. Gallin JI, Alling DW, Malech HL, et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med 2003 ; 348 : 2416–2422. [CrossRef] [PubMed] [Google Scholar]
  26. Hodiamont CJ, Dolman KM, Ten Berge IJM, et al. Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. Med Mycol 2009 ; 47 : 217–220. [CrossRef] [PubMed] [Google Scholar]
  27. Epaulard O, Leccia M-T, Blanche S, et al. Phototoxicity and photocarcinogenesis associated with voriconazole. Med Mal Infect 2011 ; 41 : 594–601. [CrossRef] [PubMed] [Google Scholar]
  28. Segal BH, Barnhart LA, Anderson VL, et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005 ; 40 : 1684–1688. [CrossRef] [PubMed] [Google Scholar]
  29. The international chronic granulomatous disease cooperative study group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991 ; 324 : 509–516. [CrossRef] [PubMed] [Google Scholar]
  30. Martire B, Rondelli R, Soresina A, et al. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin Immunol 2008 ; 126 : 155–164. [CrossRef] [PubMed] [Google Scholar]
  31. Stasia MJ. La granulomatose septique chronique X+ : un fabuleux modèle d’étude de l’activation du complexe NADPH oxydase. Med Sci (Paris) 2007 ; 23 : 526–532. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  32. Gougerot-Pocidalo MA, El Benna J, My-Chan Dang P, Elbim C. Quand les polynucléaires neutrophiles attrapent les agents pathogènes dans leurs filets. Med Sci (Paris) 2007 ; 23 : 464–465. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  33. Lamoth F, Bochud PY. Aspergillose invasive : perspectives en infectiologie préventive. Med Sci (Paris) 2009 ; 25 : 669–672. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  34. De Oliveira-Junior EB, Bustamante J, Newburger PE, Condino-Neto A. The human NADPH oxidase: primary and secondary defects impairing the respiratory burst function and the microbicidal ability of phagocytes. Scand J Immunol 2011 ; 73 : 420–427. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.